biostudies-literatureUnknown96(8)Rosner ABriLife^®, a vector-based vaccine that utilizes the recombinant vesicular stomatitis virus (VSV) platform to express and present the spike antigen of SARS-CoV-2, is undergoing testing in a phase 2 clinical trial in Israel. A nonclinical repeated-dose (GLP) toxicity study in New Zealand white rabbits was performed to evaluate the potential toxicity, local tolerance, immunogenicity and biodistribution of the vaccine. rVSV-ΔG-SARS-CoV-2-S (or vehicle) was administered intramuscularly to two groups of animals (10⁶, 10⁷ PFU/animal, n = 10/sex/group) on three occasions, at 2-week intervals, followed by a 3-week recovery period. Systemic clinical signs, local reactions, body weight, body temperature, food consumption, ophthalmology, urinalysis, clinical pathology, Archives of toxicology2329-2339https://www.ebi.ac.uk/biostudies/studies/S-EPMC9110212biostudies-literaturerVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits.PMC9110212Yahalom-Ronen YMarcus HPoliti BMadar-Balakirski NMadar-Shapiro LAchdout HTamir HStein DKronfeld NWeiss SYitzhaki SVitner EAvraham RMechaly ARosner ACherry LFatelevich EBeth-Din AMelamed SParan NLevy HIsraely TFisher MNyska ASteiner MfalserVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits.BriLife^®, a vector-based vaccine that utilizes the recombinant vesicular stomatitis virus (VSV) platform to express and present the spike antigen of SARS-CoV-2, is undergoing testing in a phase 2 clinical trial in Israel. A nonclinical repeated-dose (GLP) toxicity study in New Zealand white rabbits was performed to evaluate the potential toxicity, local tolerance, immunogenicity and biodistribution of the vaccine. rVSV-ΔG-SARS-CoV-2-S (or vehicle) was administered intramuscularly to two groups of animals (10⁶, 10⁷ PFU/animal, n = 10/sex/group) on three occasions, at 2-week intervals, followed by a 3-week recovery period. Systemic clinical signs, local reactions, body weight, body temperature, food consumption, ophthalmology, urinalysis, clinical pathology, 2022-01-01T00:00:00Z2022 Aug2026-05-31T07:10:18.492Z2025-02-19T05:04:53.496ZS-EPMC91102123557798610.1007/s00204-022-03302-5